Izzy [on for Ryan]'s questions to Xtant Medical Holdings (XTNT) leadership • Q3 2024
Question
Asked for more details on the Q3 revenue softness, the future revenue mix between orthobiologics and spinal implants, and any early outlook for 2025.
Answer
Executives attributed Q3 softness to a return of pre-COVID summer seasonality with doctor vacations, which has since normalized. They expect the revenue mix to shift more towards biologics from the current 55/45 split. For 2025, they anticipate revenue growth approaching double digits, 3-4 points of gross margin improvement, and continued operating leverage.